Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics.

Korea Institute of Radiological & Medical Sciences specializes in radiation technology, research, development, genomics, and radiotherapy.

Terapio is developing a pipeline of therapies based on the normally-occurring transport protein RLIP76 that moves free-radical toxins out of cells before significant damage can occur. Although naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.

Henan Jiade Hengli Technology Co., Ltd., established on 2017-12-11, The scope of business includes technical services for radiation health testing;Sanitation inspection and testing technical services in public places;Personal Dose Monitoring Technical Services;Occupational Safety and Health Technical Consulting,Technical Services;Safety evaluation and standardization technical consultation,Technical Services;Food Safety Hygiene Testing Service;engineering survey;Radioactive Occupational Hazard Assessment Technical Consultation,Technical Services;environmental test;Environmental technology development,technical consulting,Technical Services.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. It has three product candidates in clinical trials and six active pre-clinical programs. Onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.

BioDiem Ltd. operates as a biotechnology company. It focuses on development and commercialization of pharmaceutical and biomedical research, vaccines and infectious disease therapies and securing licences of biopharmaceutical products currently under development. The firm's development programs include: expansion of the live attenuated influenza virus-based flu vaccine licensing business, development of the antimicrobial BDM-I for the treatment of serious infectious diseases, scrambled antigen vaccine and viral vector systems. The company was founded on May 18, 2001 and is headquartered in Melbourne, Australia.

The National Institute of Radiological Sciences (放射線医学総合研究所) (NIRS) is a radiation research institute in Japan. The NIRS was established in 1957 as the Japan's only one institute of radiology. The NIRS maintains various ion accelerators in order to study the effects of radiation of the human body and medical uses of radiation.

Biothera, Inc., a biotechnology company, develops a natural gluco polysaccharide that engages and directs natural innate immune systems. Biothera was formerly known as Biopolymer Engineering, Inc. and changed its name to Biothera, Inc. in March 2005. The company was founded in 1997 and is based in Eagan, Minnesota.

Part of QIAGEN NV, QIAGEN Sciences LLC is an American company located in Germantown, MD. The firm manufactures and distributes sample and assay technology products for preanalytical sample preparations.

G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It is also advancing rintodestrant, a potential oral selective estrogen receptor degrader, or serd, for the treatment of er+ breast cancer. It is committed to improving the lives of those impacted by cancer. It is also executing a tumor-agnostic development program, with late-stage clinical trials ongoing in multiple tumor types.

Yamanouchi Pharmaceutical Co. Ltd. manufactures and markets drugs, quasi-drugs and medical devices. It used to promote collaboration with other pharmaceutical companies as well as bioventure companies and academia to raise the quality and speed of its R&D activities. It was founded in 1923. The company was headquartered in Tokyo, JP

Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company, which engages in the exploration of new methods of use of alpha-1 antitrypsin (AAT). It offers AAT, a naurally occurring protein that is essential for normal liver and lung function and has been purified from human blood to treat patients suffering from emphysema due to AAT-deficiency. The company was founded on December 1, 2005 and is headquartered in Fort Collins, CO.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Beijing High Energy Xingyuan Hotel Co., Ltd., established on 1985-06-01, Business scope includes accommodation;Chinese food;haircut;retail bakery,Dried and Fresh Fruits,drinks,liquor,cigarette;laundry;retail general merchandise.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Cleveland BioLabs is a clinical-stage biotech developing a robust pipeline of drugs for multiple medical and defense applications, with a focus on oncology and tissue protection. The company pursues the research, development, and commercialization of proprietary products that have the potential to treat cancer, prevent, and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Cleveland BioLabs was established in 2003 and is headquartered in Buffalo, New York.